KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Net Margin: 2019-2025

Historic Net Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -36.66%.

  • Esperion Therapeutics' Net Margin rose 2359.00% to -36.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -35.47%, marking a year-over-year decrease of 2145.00%. This contributed to the annual value of -1.46% for FY2024, which is 18296.00% up from last year.
  • Per Esperion Therapeutics' latest filing, its Net Margin stood at -36.66% for Q3 2025, which was down 125.56% from -16.25% recorded in Q2 2025.
  • Esperion Therapeutics' Net Margin's 5-year high stood at 42.29% during Q1 2024, with a 5-year trough of -1,140.00% in Q1 2021.
  • In the last 3 years, Esperion Therapeutics' Net Margin had a median value of -60.25% in 2024 and averaged -85.66%.
  • Its Net Margin has fluctuated over the past 5 years, first spiked by 313,267bps in 2021, then plummeted by 24,628bps in 2022.
  • Esperion Therapeutics' Net Margin (Quarterly) stood at -448.40% in 2021, then spiked by 14,634bps to -302.06% in 2022, then surged by 12,400bps to -178.06% in 2023, then spiked by 14,790bps to -30.16% in 2024, then skyrocketed by 2,359bps to -36.66% in 2025.
  • Its Net Margin was -36.66% in Q3 2025, compared to -16.25% in Q2 2025 and -63.89% in Q1 2025.